secwatch.observer — SEC 8-K summary
======================================

Issuer:     Intellia Therapeutics, Inc. (NTLA)
CIK:        0001652130
Form:       8-K
Filed at:   2023-10-18T23:59:59+00:00
Accession:  0001193125-23-258063
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA clears Intellia's IND for NTLA-2001 Phase 3 trial in ATTR cardiomyopathy
----------------------------------------------------------------------------

- First-ever in vivo CRISPR candidate to enter late-stage clinical development (Phase 3).
- Global Phase 3 study expected to initiate by year-end 2023.
- NTLA-2001 is a single-dose, systemically administered CRISPR therapy targeting TTR gene.
- Intellia collaborates with Regeneron on development and commercialization.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1652130/000119312523258063/0001193125-23-258063-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1652130/000119312523258063/d570255d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-258063

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer